All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oxypurinol
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: XRx-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The FDA response provided clear feedback on the proposed plan and outlined the critical steps to test XRx-101 in patients with COVID-19 infection to treat acute kidney injury (“AKI”).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Elezanumab
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ABT-555
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
Elezanumab is a monoclonal antibody of the human immunoglobulin (Ig)G1 isotype that binds selectively to repulsive guidance molecule A (RGMa). Elezanumab is being investigated to treat spinal cord injuries, multiple sclerosis and acute ischemic stroke.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Suramin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: REX Health Ventures
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 23, 2020
Details:
RLS will use the proceeds to fund a Phase 2 trial of suramin in diuretic resistant Acute Kidney Injury (AKI).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oxypurinol
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: XRx-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
This filing initiates formal communications with the U.S. FDA regarding development of the Company’s proprietary formulation of XRx-101 (Oxypurinol) for the treatment and prevention of acute kidney injury (AKI) associated with COVID-19 coronavirus infection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oxypurinol
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: XRx-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Icahn School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 04, 2020
Details:
XRx-101 is a proprietary of xanthine oxidase inhibitor oxypurinol. The study provides clues about the potential of XRx-101 as a treatment to suppress the severity of the coronavirus / COVID-19 infection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Daxibotulinumtoxin A
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
The company has announced a decision to complete enrollment in its JUNIPER Phase 2 trial of DaxibotulinumtoxinA for Injection for the treatment of upper limb spasticity in adults after stroke or traumatic brain injury.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LB1148
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2020
Details:
Data demonstrate efficacy on an approvable endpoint that may also result in substantial cost savings based on reductions ICU and hospital length of stay.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nangibotide
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Roche Diagnostics GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 21, 2020
Details:
Inotrem entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PB2452
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: SFJ Pharmaceuticals
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 10, 2020
Details:
The collaboration with SFJ provides PhaseBio with substantial funding to continue the rapid advancement of lead program, PB2452.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PAT-1251
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PAT-1251
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Pharmakea therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 07, 2020
Details:
The two firms will combine & put in robust fibrosis and cancer services, including a recently inhaled galectin-3 modulator ph IIb for the potential treatment of idiopathic pulmonary fibrosis.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
